By enabling instant-on and purpose-built applications(TM)
for PCs, a new platform from Phoenix will transform the
user experience with new levels of security, reliability,
ease of use, and low power consumption
MILPITAS, Calif., Nov. 5 /Xinhua-PRNewswire/ -- Phoenix
Technologies Ltd. (Nasdaq: PTEC), the global leader in core
systems firmware, today announced Phoenix HyperSpace(TM),
an innovative platform that promises to ignite a PC
revolution by transforming the mobile personal computing
experience. Enhanced by Intel(R) processor technology,
Phoenix HyperSpace(TM) provides a secure foundation of
`embedded simplicity.' PC OEMs can now offer
highly-efficient, instantly available applications that
promise to deliver new levels of security, up-time, system
reliability, remote management, and ease-of-use to PC
users.
( Logo:
http://www.newscom.com/cgi-bin/prnh/20070410/SFTU048LOGO )
The HyperSpace platform provides a unique computing
environment that PC designers, security innovators and
content providers can use to create instant-on applications
that are available before, during, and after Windows boot up
and shut down. Operating like self-contained appliances,
these purpose-built applications will be embedded into new
computers by PC system vendors. Next-generation PC users
will benefit from one-click remote system maintenance,
repair, lower battery consumption and embedded security
providing stronger protection than is currently available,
along with a host of possible applications and content such
as instant-on multi-media players, IP soft phones, email,
instant messaging, Web 2.0 browsing, safe shopping and
more. Phoenix has already demonstrated prototype,
proof-of-concept applications that show the possibilities
of the new HyperSpace platform.
HyperSpace delivers an elegant, high-performance, low
battery-consumption environment which enables mobile PC
users to be productive at all times.
"For most of us, today's computing experience is a
lot like air travel -- offering tremendous possibilities,
but plagued with security issues, delays and system
failures," said Woody Hobbs, President & CEO of
Phoenix Technologies. "HyperSpace introduces a new
framework to transform the personal computing experience
through purpose-driven appliances(TM) that work within the
HyperSpace environment. Working together with our partners
within the PC ecosystem, we believe HyperSpace will ignite
a new revolution of innovation built on the foundation of
embedded simplicity."
The HyperSpace platform is enabled by an efficient
hypervisor from Phoenix called HyperCore(TM), which is
embedded within the core system firmware, or BIOS.
HyperCore is a lightweight Zoned Virtual Machine Monitor
(ZVMM) that runs specialized core services side-by-side
with Windows.
HyperSpace products will offer isolation and high
performance delivered by optimizing HyperSpace for
capabilities delivered in Intel(R) Core(TM) 2 Duo
processors, Intel(R) vPro(TM) and Intel(R) Centrino(TM) Pro
processor technology, including enhanced Intel(R)
Virtualization Technology and Intel(R) Trusted Execution
Technology.
"Intel(R) Core(TM) 2 Duo processors and Intel(R)
vPro(TM) processor technology enable the development of
more secure and better performing virtualization
infrastructure," said Gregory Bryant, Vice President
and General Manager for Intel's Digital Office Platform
Division. "Intel is pleased to see Phoenix embracing
Intel's technologies to deliver innovative products for PC
clients."
Leslie Fiering, Research VP at Gartner, said,
"Client computing combines two worlds -- on one side,
users want their work and personal lives to be empowered by
an instant-on and always available PC with ubiquitous
network access and easy-to-use applications. On the
business side, beleaguered IT organizations are working
with shrinking budgets and face growing concerns over
security. The industry will welcome a solution that holds
the promise of satisfying both PC user needs as well as IT
remote management and security needs."
Phoenix Technologies is actively collaborating with
industry partners, PC OEMs/ODMs, ISVs and Web 2.0 providers
to introduce the next-generation of PCs with embedded
simplicity.
About Phoenix Technologies
Phoenix Technologies Ltd. (Nasdaq: PTEC) is the global
market leader in systems firmware that provides the most
secure foundation for today's computing environments. The
Company established industry leadership with its original
BIOS product in 1983, and today has 155 technology patents,
has shipped in over one billion systems, and continues to
ship in over 125 million new systems each year. The PC
industry's top builders and specifiers trust Phoenix to
pioneer open standards and deliver innovative solutions to
help them accelerate time to market, differentiate products
and increase profits. Phoenix is headquartered in Milpitas,
California with offices worldwide. For more information,
visit http://www.phoenix.com.
Phoenix, Phoenix Technologies, and the Phoenix
Technologies logo are trademarks and/or registered
trademarks of Phoenix Technologies Ltd. All other
trademarks are the property of their respective owners.
Safe Harbor
With the exception of historical information, the
statements in this release include forward-looking
statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, regarding, but
not limited to, the potential transformative impact of the
HyperSpace platform and the HyperCore hypervisor on the PC
industry and PC users, the functionality and features of
this new platform, the adoption of this new platform by
Phoenix's partners and customers, and the potential
applications that may be based on this new platform These
statements involve risks and uncertainties, including:
unexpected technical challenges and delays, including code
bugs and glitches; the product offerings of competitors,
especially with respect to functionality and
time-to-market; price competition; our ability to
successfully market and sell the HyperSpace platform to our
customers; the ability of our customers to introduce and
market products that incorporate and leverage the
HyperSpace platform; end-market demand for applications
that may be enabled by the HyperSpace platform; and our
ability to adequately protect our intellectual property
rights. For a further list and description of risks and
uncertainties that could cause actual results to differ
materially from those contained in the forward looking
statements in this release, we refer you to the Company's
filings with the Securities and Exchange Commission,
including, but not limited to, its annual report on Form
10-K and quarterly reports on Form 10-Q. All
forward-looking statements included in this release are
based upon assumptions, forecasts and information available
to the Company as of the date hereof, and the Company
assumes no obligation to update any such forward-looking
statements.
For more information, please contact:
Media & Analyst Relations:
Phoenix Technologies,
Global Communications
Tel: +1-408-570-1946
Email: public_relations@phoenix.com
Scott Vansickle
Global Fluency
Tel: +1-650-433-4222
Email: svansickle@globalfluency.com
Structure Provides Flexibility to Initiate Company's
Planned 100 Megawatt Thin Film Solar Module Production
Facility Build Out
ALISO VIEJO, Calif., Nov. 5 /Xinhua-PRNewswire/ --
XsunX, Inc. (OTC Bulletin Board: XSNX), announced today
that it has secured a total of $21,000,000 in financing
with Fusion Capital Fund II, LLC, a Chicago-based
institutional investor, to support the launch of its phased
plans to build a 100 megawatt amorphous silicon thin film
photovoltaic (TFPV) solar module manufacturing facility.
Over the course of 2007, the Company designed a
proprietary 25 megawatt TFPV solar module manufacturing
system, and developed a phased plan to build and install
four of these systems by 2010. XsunX then worked with
industry proven and recognized vendors to ensure access to
materials and components necessary to meet build schedules
under its phased plan.
Next, XsunX solicited proposals from over twenty states
to ensure that the Company benefited from establishing its
new manufacturing facilities in a region providing strong
business incentives and an educated workforce. After a
review of all submitted proposals, XsunX made a decision to
locate their multi-megawatt manufacturing facilities in the
State of Oregon, USA. This decision was based on a
combination of operating incentives and credits, added to
low cost financing opportunities, submitted by the State of
Oregon.
XsunX then worked to introduce the design and future
availability of its XASI-120 solar module to the solar
installation industry at key trade shows. These efforts
have resulted in over 90 megawatts of module
pre-manufacture reservations. Finally, the Company set out
to select a strong investment partner and the right
investment structure to finance the first stages of the
planned build out of its TFPV manufacturing facilities.
Mr. Tom Djokovich, XsunX's CEO, stated, "We owed
our investors a well defined plan leveraging a solid mix of
key employees, premier vendors, government support, and
access to working capital under the best terms, without the
burden of unnecessary debt instruments found in many
financing agreements. I believe that taking the time to put
all of the pieces in place was crucial to providing XsunX
the best opportunity for success. One of the last aspects
to our plan was to find a solid financing partner that was
interested in our business. We looked at quite a few term
sheets and, in selecting Fusion Capital, I believe that we
found the support we needed on the terms that work best for
all of our investors."
Upon signing the stock purchase agreement, XsunX
received $1,000,000 from Fusion Capital as an initial
purchase of common stock under the $21 million commitment,
at a price of $.30 per share. After the SEC has declared
effective a registration statement related to the
transaction, the Company has the right, over a 25-month
period, to sell its shares of common stock to Fusion
Capital, from time to time, in amounts up to $1 million per
sale, depending on certain conditions as set forth in the
stock purchase agreement, up to the full aggregate
commitment of $21 million.
The purchase price of the shares related to the $20
million balance of future funding will be based on the
prevailing market prices of the Company's shares at the
time of sales without any fixed discount, and the Company
will control the timing and amount of any sales of shares
to Fusion Capital. There are no negative covenants,
restrictions on future fundings, penalties or liquidated
damages in the agreement. The common stock purchase
agreement may be terminated by XsunX at any time at its
discretion without any additional cost to XsunX.
The proceeds received by the Company under the common
stock purchase agreement are expected to be used to build
an initial base production system delivering full size
commercial quality solar modules, and initiate the
manufacture of the first of four (4) planned 25 megawatt
systems under the Company's planned 100 megawatt thin film
solar module production facility. Proceeds may also be used
to lease and prepare manufacturing facilities with the
necessary support systems for the manufacturing line,
inventory, staff, and general working capital.
A more detailed description of the agreement is set
forth in the Company's Current Report on Form 8-K recently
filed with the SEC which the Company encourages be reviewed
carefully.
About XsunX
Fusion Capital Fund II, LLC is an institutional
investor based in Chicago, Illinois with a fundamental
investment approach. Fusion Capital invests in a wide
range of companies and industries emphasizing life
sciences, energy and technology companies. Its investments
range from special situation financing to long-term
strategic capital.
About Fusion Capital
Fusion Capital Fund II, LLC is an institutional
investor based in Chicago, Illinois with a fundamental
investment approach. Fusion Capital invests in a wide
range of companies and industries emphasizing life
sciences, energy and technology companies. Its investments
range from special situation financing to long-term
strategic capital.
Safe Harbor Statement:
Matters discussed in this press release contain
forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. When used
in this press release, the words "anticipate,"
"believe," "estimate," "may,"
"intend," "expect" and similar
expressions identify such forward-looking statements.
Actual results, performance or achievements could differ
materially from those contemplated, expressed or implied by
the forward-looking statements contained herein. These
forward-looking statements are based largely on the
expectations of the Company and are subject to a number of
risks and uncertainties. These include, but are not limited
to, risks and uncertainties associated with: the impact of
economic, competitive and other factors affecting the
Company and its operations, markets, product, and
distributor performance, the impact on the national and
local economies resulting from terrorist actions, and U.S.
actions subsequently; and other factors detailed in reports
filed by the Company.
For more information, please contact:
Investor Relations
XsunX, Inc.
Tel: +1-888-797-4527
Web: http://www.XsunX.com
BASINGSTOKE, England, Nov. 5 /Xinhua-PRNewswire/ -- New
data presented today at the 40th annual American Society of
Nephrology (ASN) meeting and scientific exposition in San
Francisco, CA, USA, show that epoetin delta -- the only
erythropoiesis-stimulating agent (ESA) produced in a human
cell line -- has less pronounced angiogenic properties than
darbepoetin alfa in vitro at similar pharmacokinetic
concentrations.(1)
Angiogenesis, the formation of new blood vessels from
pre-existing vessels, plays an important role in tumour
growth, malignancy and diabetic retinopathy. The study
evaluated the angiogenic potential of human cell-derived
epoetin delta and darbepoetin alfa at broad concentration
ranges using a novel in vitro model that incorporates key
aspects of the complex angiogenesis process.(1)
"Although this research is at a very early stage,
this data is the first step towards evaluating whether
different EPO analogues produce different angiogenic
effects," said primary investigator Professor Alan
Stitt, Centre for Vision Science, Queen's University,
Belfast, Northern Ireland, UK. "In the clinical
setting, there are situations where reduced angiogenic
potential is beneficial, for example, in patients with
malignancies or proliferative retinopathy. Additional
studies, in both the non-clinical and clinical setting, are
needed to further examine the angiogenic potential and
related molecular mechanisms of epoetin delta."
The authors of the study concluded that the observed
pharmacological effects of epoetin delta and darbepoetin
alfa on the angiogenic response may be associated with
their different glycosylation patterns at clinically
relevant doses.(1) Glycosylation (the process of adding
carbohydrate structures to a protein) is dependent on
various factors including species and cell type.(2) As
epoetin delta is produced in human cells by activating the
erythropoietin gene -- and all other commercially available
ESAs are presently made in Chinese Hamster Ovary (CHO) cells
-- epoetin delta has a different glycosylation pattern to
other currently marketed ESAs.(3)
Neuropathy also commonly develops in people with
diabetes who also suffer from CKD. Additional non-clinical
data accepted for publication at ASN show that in rats,
epoetin delta corrects the reduced nerve conduction
velocity (a parameter of nerve function) associated with
neuropathy. This occurred even at doses below those
promoting haematopoiesis.(4)
"This data is particularly interesting," said
primary investigator Professor Norman E Cameron, School of
Medical Sciences, University of Aberdeen, Scotland.
"We know that ESAs are effective in correcting
anaemia, but this data suggests that, at least in the
non-clinical setting, epoetin delta may have pleiotropic,
non-hematopoietic effects. Further research is needed to
investigate whether structural differences across ESA
analogues influence diabetic co-morbidities, such as
diabetic neuropathy, differently."
To further understand the implications of epoetin delta
being manufactured in a human cell line, Shire is sponsoring
a non-clinical research programme to investigate how epoetin
delta affects tissues and processes outside of the
haematopoietic system. Of particular interest is whether
epoetin delta's human cell derivation may influence
co-morbidities of the renal anaemia patient, such as
diabetic complications and vascular disease, in a way that
is different to ESA's derived from animal cells. The
research presented today marks the publication of the first
data from the programme.
About DYNEPO
DYNEPO is the first commercially available ESA produced
in a human cell line.(5) This is accomplished by activating
the endogenous human erythropoietin gene in a human cell
line using specialised gene-activating DNA sequences.(6)
All other commercially available ESAs are produced in CHO
cells. Anaemic patients with CKD require treatment with an
ESA such as DYNEPO in order to increase red blood cell
production.
DYNEPO is indicated for the treatment of anaemia in
patients with chronic renal failure (CRF) and may be used
in patients on dialysis and in patients not on
dialysis.(7)
DYNEPO is a registered trademark of Hoescht GmbH.
(i) While common terminology is now chronic kidney
disease (CKD), some regulatory agencies have not adopted
this terminology, instead they refer to chronic renal
failure (CRF); these terms are essentially
interchangeable.
Notes to editors
Shire plc
Shire's strategic goal is to become the leading
specialty biopharmaceutical company that focuses on meeting
the needs of the specialist physician. Shire focuses its
business on attention deficit and hyperactivity disorder
(ADHD), human genetic therapies (HGT), gastrointestinal
(GI) and renal diseases. The structure is sufficiently
flexible to allow Shire to target new therapeutic areas to
the extent opportunities arise through acquisitions.
Shire's in-licensing, merger and acquisition efforts are
focused on products in niche markets with strong
intellectual property protection either in the US or
Europe. Shire believes that a carefully selected portfolio
of products with strategically aligned and relatively
small-scale sales forces will deliver strong results.
The "Safe Harbor" Statement Under the Private
Securities Litigation Reform Act of 1995
Statements included herein that are not historical
facts are forward-looking statements. Such forward-looking
statements involve a number of risks and uncertainties and
are subject to change at any time. In the event such risks
or uncertainties materialize, Shire's results could be
materially affected. The risks and uncertainties include,
but are not limited to, risks associated with: the inherent
uncertainty of pharmaceutical research; product development
including, but not limited to, the successful development
of JUVISTA(R) (Human TGF beta 3) and GA GCB (velaglucerase
alfa); manufacturing and commercialization including, but
not limited to, the launch and establishment in the market
of VYVANSE(TM) (Attention Deficit and Hyperactivity
Disorder ("ADHD"); the impact of competitive
products including, but not limited to, the impact of those
on Shire's ADHD franchise; patents including, but not
limited to, legal challenges relating to Shire's ADHD
franchise; government regulation and approval including,
but not limited to, the expected product approval date of
INTUNIV(TM) (guanfacine extended release) (ADHD); Shire's
ability to secure new products for commercialization and/or
development; and other risks and uncertainties detailed from
time to time in Shire plc's filings with the Securities and
Exchange Commission, particularly Shire plc's Annual Report
on Form 10-K for the year ended December 31, 2006.
References
(1) McVicar C, Gardiner T, Stitt A. Human-cell-derived
epoetin delta is less angiogenic than darbepoetin alfa in
vitro. Poster presented at American Society of Nephrology
Renal Week, San Francisco, CA, USA. 2-5 November 2007.
(2) Skibeli V, Nissen-Lie G, Torjesen P. Sugar
profiling proves that human erythropoietin differs from
recombinant human erythropoietin. Blood 2001; 98(13):
3626-3634.
(3) Shahrokh Z, Flatman S, Davies M, et al.
Erythropoietin produced by a human cell line has only trace
levels of potentially immunogenic N-glycolylneuraminic acid
residues. Presented at the European Haematology Association
11th Annual Congress, Amsterdam, The Netherlands. 15-18 June
2006.
(4) Cameron N and Cotter M. Potential benefits of
epoetin delta in diabetic rats: focus on neuropathy.
Abstract accepted at American Society of Nephrology Renal
Week, San Francisco, CA, USA. 2-5 November 2007.
(5) Pratt, R. Epoetin delta for the treatment of anemia
in patients with CKD not requiring hemodialysis. Poster
presented at American Society of Nephrology Renal Week, San
Diego, CA, USA; 14-19 November 2006
(6) Deicher R and Horl W. Differentiating factors
between erythropoiesis-stimulating agents. Drugs 2004;
64(5): 499-509.
(7) DYNEPO Summary of Product Characteristics. Shire
Pharmaceuticals. April 2007.
For further information on Shire, please visit the
Company's website: http://www.shire.com.
For more information, please contact:
Investor Relations:
Clea Rosenfeld
Phone: +44-1256-894-160
Media Shire:
Jessica Mann
Phone: +44-1256-894-280
Media PR agents for DYNEPO:
Resolute Communications
May Baccari
Phone: +44-207-357-8187
Kirsty Mearns
Phone: +44-207-357-8187
- Good Perspectives for Sino-Berlin Business Relations
BERLIN, Nov. 5 /Xinhua-PRNewswire/ -- Berlin Mayor and
Senator for Economics, Technology, and Women's Affairs
Harald Wolf will be visiting Hong Kong, Shenzhen, and
Beijing November 7-12, where he'll be meeting and holding
talks with politicians and business representatives.
Senator Wolf says of his trip, "I intend to entrench
existing contacts, and inform Chinese companies about the
opportunities for investment in Berlin. A new airport is
currently being built in Berlin that is an hour's flight
closer to Asia than any other European airport that can be
reached directly by air."
Berlin is one of only two German cities in the list of
the top 50 foreign investment locations for Chinese
companies compiled by the Chinese Economics Ministry and
the China International Institute of Multinational
Corporations.
At present there are about 200 Chinese-run firms in
Berlin, and another 20 or so are planning to settle there.
Some 6,000 Chinese live in the German capital city.
Berlin-based companies increased their trade with China by
a factor of six from 1996 to 2006. Over the same period,
imports from China rose more than fivefold.
In Hong Kong Senator Wolf is due to hold talks with
municipal leaders and visit the science park. In Shenzhen
he will be visiting HYT, a radio device manufacturer. He
will also be attending the Shenzhen-Berlin Economic
Cooperation Forum, where he will present the investment
opportunities in Berlin to representatives from several
hundred Chinese companies. In Beijing the senator will be
visiting the Berlin Olympic Pavilion and find out more
about the Sino-German co-production 'Laura's Star II'
involving Berlin-based animation company Cartoon Film.
In all three cities he will be talking to airlines
interested in operating direct flights to Berlin. The
construction of the new Berlin-Brandenburg International
Airport (BBI) will create the most modern airport in
Europe. The BBI is due to begin operating in 2011, and is
expected to process an initial 25 million passengers a
year, though it will have the capacity to handle up to 40
million. Given its proximity to Asia vis-a-vis other
European airports, the BBI will be ideal for new direct
connections between the two continents.
The Berlin delegation's trip was organized by Berlin
Partner GmbH, the company commissioned by the Berlin
government to attract investors, advise local companies on
foreign trade, and market the German capital city.
Further information about Berlin Partner (in German and
Chinese): http://www.berlin-china.net
Further information about the investor conference (in
English and Chinese): http://www.shenzhen-berlin.com
For more information, please contact:
Berlin Partner GmbH
Ludwig Erhard Haus
Fasanenstrasse 85
D-10623 Berlin
Website: http://www.berlin-partner.de
Christoph Lang
Head, Press and Public Relations
Tel: +49-30-39980-123
Fax: +49-30-39980-113
Mobile: +49-1577-3998-123
Email: Christoph.Lang@berlin-partner.de
HONG KONG, Nov. 5 /Xinhua-PRNewswire/ -- Arrow Asia Pac
Ltd., a business unit of Arrow Electronics, Inc. (NYSE:
ARW), announced that it was ranked among the top-five
companies in the InformationWeek China 100, an annual
listing of the most innovative users of information
technology in China.
(Logo: http://www.xprn.com/xprn/sa/200703021139.JPG )
"We are honored to be recognized again as one of
China's most innovative users of information technology in
the InformationWeek China 100 listing," said Peter
Kong, president of Arrow Asia Pac. "This recognition
clearly reflects our industry leadership position. In our
journey to be the clear number one in Asia, we will
continue to create a competitive advantage and deliver
value for our customers and suppliers through utilizing
technology to accelerate improvements in business
processes."
The InformationWeek China 100 considered over 6,000
companies from 35 industries in mainland China. It
included a quantitative and qualitative analysis of
technology initiatives and priorities, and responses were
evaluated and weighted and combined into a total score that
formed the basis for the ranking.
About Arrow Asia Pac
A business unit of Arrow Electronics, Inc. (NYSE: ARW),
Arrow Asia Pac is one of Asia-Pacific's leading electronic
component distributors. In addition to its regional
headquarters in Hong Kong, Arrow Asia Pac operates 51 sales
offices, four primary distribution centers and 12 local
warehousing facilities in 11 countries/territories across
Asia.
Providing a full range of semiconductors, passive,
electromechanical and connector products from over 170
leading international suppliers, Arrow Asia Pac serves more
than 10,000 original equipment and contract manufacturers
and commercial customers in Asia-Pacific. Visit us at
http://www.arrowasia.com .
For more information, please contact:
Ray Leung
Marketing Communications Director
Arrow Asia Pac Ltd.
Tel: +852-2484-2484
Email: marcom.asia@arrowasia.com
Grace Kung
Marketing Communications Manager
Tel: +852-2484-2682
Email: grace.kung@arrowasia.com
LONDON, Nov. 5 /Xinhua-PRNewswire/ -- At FI Europe, the
world's largest food ingredients event, with a record
breaking 23000 visitors and over 1,000 exhibitors in London
this week, a distinguished panel of judges has awarded its
prestigious Gold Award to EBI Food Safety of The
Netherlands.
In its fight against Listeria, and other dangerous
bacteria, the food industry has embraced a 'green'
solution, using bacteriophages as the way to go. EBI Food
Safety, first-to-market with a commercial bacteriophage
product, fended off competition from eight other finalists
to scoop the Oscar of the Food Industry, for its LISTEX(TM)
product against Listeria monocytogenes, the deadly food
pathogens.
At a glittering ceremony in London's Excel Centre, the
awards came at the end of a day of non-stop deliberation by
the judges. "This year's FI Awards have been the most
exciting ever" said Henry Dixon, chairman of the
judging committee and director of international food
marketing communications agency Barret Dixon Bell. "We
received over 50 entries, and had a really good spread of
innovations and market factors. They were extremely strong
finalists".
"LISTEX(TM) is a true innovation, a new approach
to an urgent and growing problem that affects both
consumers and manufacturers" said Dixon, explaining
the judges' reason for choosing EBI Food Safety as the
winner of the Gold Award. The FI Awards, which have been
running since 1994, are one of the most eagerly anticipated
events in the food industry calendar, and this year was no
exception. "I think the FI Awards are particularly
special in that they really make a difference - as
evidenced by the amount of interest that has been shown in
them - journalists from around the globe have been
desperate to find out who has won", said Dixon.
LISTEX(TM) effectively eliminates Listeria
monocytogenes, without affecting the other properties of
the food. It is a safe and natural product, which is easy
to apply in a variety of Listeria-susceptible products,
such as hams and hot dogs, cheese, fish and many
RTE-products. It addresses a multi-billion dollar industry
problem, on account of Listeria's high mortality (20-30%)
and ability to grow at refrigerated temperatures and in low
oxygen environments such as packaged foods. First associated
with a food borne outbreak in 1981, killing 7, Listeria
monocytogenes is now responsible for almost half of all
deaths caused by food pathogens. Other potentially fatal
pathogens are Salmonella, Campylobacter and E-coli, for
which EBI Food Safety is also developing bacteriophage
products.
EBI Food Safety's CEO, Mark Offerhaus: "We are
honoured by the judges' decision. This choice is a
confirmation from the industry that the use of phages is a
logical one. Last month the largest frozen hamburger
producer in the US went out of business, just two weeks
after it's first ever product recall. The consequences of a
contaminated product reaching the market can be
catastrophic. Use of natural phages translates into
risk-reduction, valued by shareholders and consumers
alike."
About EBI Food Safety
EBI Food Safety (http://www.ebifoodsafety.com), located
in Wageningen ("Food Valley"), The Netherlands,
develops and markets natural bacteriophage products against
dangerous food pathogens and is viewed as product leader in
this field. Earlier this year EBI Food Safety was elected
as one of Holland's 25 most promising young enterprises by
FEM Business Magazine. The company's scientific network
includes collaborations with universities and research
centers around the world.
For more information, please contact:
Mark Offerhaus, CEO
EBI Food Safety
Phone: +31-0-654-913-176
Email: m.offerhaus@ebifoodsafety.com or
info@ebifoodsafety.com
Investigational compound reduces risk of major
cardiovascular events by 19 percent, significantly improves
net clinical benefit despite increased bleeding
TOKYO and INDIANAPOLIS, Nov. 5 /Xinhua-PRNewswire/ --
In the pivotal Phase III head-to-head TRITON TIMI-38
clinical trial, the investigational antiplatelet agent
prasugrel produced a highly significant 19 percent
reduction in relative risk (p=0.0004) for the composite
endpoint of cardiovascular death, non-fatal heart attack or
non-fatal stroke when compared with clopidogrel
(Plavix(R)/Iscover(R)) in the treatment of patients across
the full spectrum of acute coronary syndrome undergoing
percutaneous coronary intervention.
( Logo:
http://www.newscom.com/cgi-bin/prnh/20070601/CLF003LOGO )
A significant reduction in the risk for the composite
endpoint favoring prasugrel (60 mg loading dose/10 mg
maintenance dose) over clopidogrel (300 mg LD/75 mg MD) was
observed as early as three days. The absolute difference in
this endpoint continued to increase over the course of the
15-month, 13,608-patient trial.
In the important subgroup of patients with diabetes,
prasugrel reduced the relative risk of cardiovascular
death, non-fatal myocardial infarction and non-fatal stroke
by 30 percent (p<0.001). In addition, in the key
secondary endpoint of stent thrombosis, prasugrel reduced
the recurrence of stent thrombosis (a new clot that
develops at the stent site) by 52 percent (p<0.0001).
TRITON also showed that treatment with prasugrel
significantly reduced the relative risk of cardiovascular
death, non-fatal heart attack and non-fatal stroke by 21
percent in patients with STEMI (ST-elevation myocardial
infarction, or high-risk heart attack) (p=0.02) and 18
percent in patients suffering from UA (unstable angina, or
chest pain)/NSTEMI (non-STEMI) (p=0.002). In addition,
prasugrel-treated patients experienced a 34 percent decline
in urgent target vessel revascularization (a procedure to
reopen blocked arteries) (p<0.001) and a 42 percent
reduction in heart attack with subsequent death from
cardiovascular causes (p=0.02).
While the overall incidence of non-CABG (coronary
artery bypass grafting) bleeding in TRITON was low in both
the prasugrel and clopidogrel treatment groups,
prasugrel-treated patients experienced a statistically
significant increase in non-CABG (coronary artery bypass
grafting) major bleeding compared to clopidogrel-treated
patients (2.4 vs. 1.8 percent, or 146 vs. 111 patients,
p=0.03), including higher rates of life-threatening
bleeding (1.4 vs. 0.9 percent, or 85 vs. 56 patients,
p=0.01). Though infrequent, fatal bleeding was
statistically more frequent among prasugrel-treated than
clopidogrel-treated patients (0.4 percent vs. 0.1 percent,
or 21 vs. five patients, p=0.002). However, death from
cardiovascular causes occurred less frequently among
prasugrel-treated patients than clopidogrel-treated
patients (2.1 percent vs. 2.4 percent, or 133 vs. 150
patients, p=0.31), as did all-cause death (3.0 percent vs.
3.2 percent, or 188 vs. 197 patients, p=0.64).
The study identified three distinct patient
subpopulations with a higher risk of major bleeding in both
treatment arms - patients who were 75 years of age or older,
weighed less than 60 kg (132 lbs.), or had a prior history
of transient ischemic attack (TIA) or stroke. Researchers
are evaluating pharmacokinetic data from several prasugrel
studies, including TRITON, to determine whether a lower
dose of prasugrel might be appropriate for some patients.
Among patients without any of these risk factors (80
percent of the 13,608-patient TRITON study), there was no
significant difference in major bleeding between prasugrel-
and clopidogrel-treated patients (2 percent vs. 1.5 percent,
p=0.17).
Based on an analysis using the combined endpoint of
all-cause death, heart attack, stroke and major bleeding,
the net clinical benefit for prasugrel compared with
clopidogrel was a significant 13 percent reduction in
overall events (12.2 vs. 13.9, p=0.004). In the
subpopulations defined as being at greater risk of
bleeding, the net clinical benefit was not different
between prasugrel- and clopidogrel-treated patients
(p=0.43). Without the subpopulations defined as being at
greater bleeding risk, the net clinical benefit was 20
percent (10.2 vs. 12.5, p<0.001).
Overall, for every 1,000 people treated with prasugrel
compared to clopidogrel in the study, there were 23 fewer
heart attacks and an additional six major bleeding
complications.
"Our study provides compelling evidence that the
prasugrel regimen tested is superior to standard dose
clopidogrel as an antiplatelet therapy to support patients
undergoing coronary stenting," said Elliott Antman,
M.D., senior investigator with the TIMI Study Group at
Harvard Medical School and director of the Samuel A. Levine
Cardiac Unit at Brigham and Women's Hospital in Boston.
"With the data from TRITON and other studies, we
expect to define populations at particular bleeding risk to
help establish clear guidance for using this promising
therapy."
Antman announced the initial study results today at the
American Heart Association's 2007 Scientific Sessions in
Orlando, Florida (abstract 07-LBCT-20660-AHA). Prasugrel is
being co-developed by Daiichi Sankyo Company, Limited (TSE:
4568) and Eli Lilly and Company (NYSE: LLY).
"The TRITON data demonstrate the statistical
superiority of this new antiplatelet therapy to prevent
heart attacks, and validate our decision to test prasugrel
head to head against clopidogrel," said J. Anthony
Ware, M.D., Lilly cardiovascular platform leader for
prasugrel. "We are very pleased with the trial's
outcome and are excited by the potential for these results
to help us further tailor prasugrel therapy to assure the
greatest benefit from this novel treatment."
Cardiovascular disease is the leading cause of death in
the U.S. and worldwide, killing 16.7 million people each
year(i). Acute heart attacks and unstable angina, called
acute coronary syndrome, affect more than 840,000 Americans
each year and 800,000 in Europe(i,ii). Utilizing current
medical interventions and treatments, 300,000 people
continue to experience recurrent heart attacks and 450,000
people die from heart attacks annually in the U.S(iv).
"TRITON confirms the statistically superior
clinical benefit of prasugrel as a third-generation oral
antiplatelet that may advance cardiovascular care,"
said John Alexander, M.D., M.P.H., global head of research
and development, Daiichi Sankyo Company, Limited.
"Given the promising TRITON results, Daiichi Sankyo
and Lilly are expeditiously finalizing our submission
package and are still hopeful to submit to the FDA by year
end."
About the TRITON TIMI-38 study
TRITON TIMI-38 was a Phase III, multi-center,
randomized, double blind, parallel group, head-to-head
clinical trial comparing the effects of prasugrel versus
clopidogrel in patients with acute coronary syndrome
undergoing percutaneous coronary intervention (PCI). PCI is
a procedure to open blockages in heart arteries including
the use of coronary stenting. The study enrolled 13,608
patients at 707 trial sites in 30 countries.
The primary endpoint of the study was to compare the
effects of prasugrel to clopidogrel on the composite
incidence of cardiovascular death, non-fatal heart attack
and non-fatal stroke during a median period of at least 12
months following PCI. Key secondary objectives included
rehospitalization for a cardiac ischemic event; the need
for additional procedures to restore blood flow (urgent
target vessel revascularization) at 30 days; and stent
thrombosis. Key safety endpoints included non-CABG major,
life threatening and minor bleeding as well as the overall
safety and tolerability of prasugrel.
Patients were randomly assigned to one of two treatment
groups and given a loading dose of either prasugrel 60 mg or
the approved loading dose of clopidogrel 300 mg anytime
between randomization and one hour after the completion of
the PCI procedure, followed by a daily maintenance dose of
either prasugrel 10 mg or clopidogrel 75 mg. All patients
also received a daily low dose of aspirin.
Antiplatelet agents are critical for both acute and
maintenance therapy to inhibit platelet activation and
subsequent aggregation that occur in diseased arteries and
as adjunct therapy to invasive procedures such as
percutaneous coronary intervention.
About prasugrel
Daiichi Sankyo Company, Limited (TSE: 4568), and Eli
Lilly and Company (NYSE: LLY) are co-developing prasugrel,
an investigational oral antiplatelet agent invented by
Daiichi Sankyo and its Japanese research partner Ube
Industries, Ltd., as a potential treatment, initially for
patients with acute coronary syndrome undergoing PCI.
Prasugrel works by inhibiting platelet activation and
subsequent aggregation by blocking the P2Y12 adenosine
diphosphate (ADP) receptor on the platelet surface.
Antiplatelet agents prevent platelets from clumping or
sticking together, which can result in clogged arteries and
may lead to heart attack or stroke.
About Daiichi Sankyo Company, Limited
Daiichi Sankyo Company, Limited, established in 2005
after the merger of two leading century-old Japanese
pharmaceutical companies, is a global pharmaceutical
innovator, continuously generating innovative drugs that
enrich the quality of life for patients around the world.
The company uses its cumulative knowledge and expertise in
the fields of cardiovascular disease, cancer, metabolic
disorders, and infection as a foundation for developing an
abundant product lineup and R&D pipeline.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is
developing a growing portfolio of first in class and
best-in-class pharmaceutical products by applying the
latest research from its own worldwide laboratories and
from collaborations with eminent scientific organizations.
Headquartered in Indianapolis, Ind., Lilly provides answers
- through medicines and information - for some of the
world's most urgent medical needs.
This press release contains certain forward-looking
statements about the potential of the investigational
compound prasugrel (CS-747, LY640315) and reflects Daiichi
Sankyo's and Lilly's current beliefs. However, as with any
pharmaceutical compound under development, there are
substantial risks and uncertainties in the process of
development and regulatory review. There is no guarantee
that the compound will receive regulatory approval, that
the regulatory approval will be for the indication(s)
anticipated by the companies, or that later studies and
patient experience will be consistent with study findings
to date. There is also no guarantee that the compound will
prove to be commercially successful. For further discussion
of these and other risks and uncertainties, see Lilly's
filing with the United States Securities and Exchange
Commission and Daiichi Sankyo's filings with the Tokyo
Stock Exchange. Daiichi Sankyo and Lilly undertake no duty
to update forward-looking statements.
Plavix(R)/Iscover(R) are registered trademarks of
Sanofi-Synthelabo Inc.
P-LLY
(i) World Health Organization. The Atlas of Heart
Disease and Stroke - Types of Cardiovascular Disease 2005.
(ii) American Heart Association. Heart Disease and
Stroke Statistics - 2006 Update. Dallas, TX. American
Heart Association.
(iii) Bertrand CURE study
(iv) American Heart Association. Heart Attack and
Angina Statistics. URL:
http://www.americanheart.org/presenter.jhtml?identifier=4591.
Last accessed July 26, 2007.
For more information, please contact:
Joedy Isert
Eli Lilly and Company
Cell: +1-317-276-5592 / +1-317-997-8544
Jo-ann Straat
Daiichi Sankyo (USA)
Tel: +1-973-359-2602
Shigemichi Kondo
Daiichi Sankyo (Tokyo)
Tel: +81-3-6225-1126
| 2007年12月03日 プレスリリース ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 留学支援大手の株式会社ゲートウェイ21（所在地：東京都新宿区 代表取締役社長：福井伴昌）は、2007年12月3日より携帯電話向け海外留学情報提供サービス、『留学するならゲートウェイ２１』を開始する。 『留学するならゲートウェイ２１』では、ゲートウェイ２１の業界最大級のネットワークを活かし、同社が世界１３ヶ国３１都市に展開する留学プログラムを国別、ジャンル別に紹介。特に、携帯のメインユーザーである10代20代に人気の高い、短期語学留学やホームステイ、ワーキングホリデー、大学留学などのコースを中心に紹介している。
◆対応キャリア： 【株式会社ゲートウェイ２１】
株式会社ゲートウェイ２１ |
| 2007年12月03日 報道関係者各位 ２００７年１２月０３日 ◆１位は「花王：メリーズ」２位は「P&G：パンパース」～「かぶれない」 たくさんある赤ちゃんの紙おむつ、何を基準に選べばいい？そこでアンケ ■１位「花王：メリーズ」２４．９％ ■２位「P&G：パンパース」２１．２％ ■３位「ユニチャーム：ムーニー」 その他、コストパフォーマンス重視で「ユニチャーム：マミーポコ」が１３． 詳しいアンケートデータは、はアンケートデータバンクで販売しています。
アンケートデータバンクでは、今後も生活全般に関するアンケート調査を実 《ご担当記者様へ》出産、子育てに関する記事のデータおよび情報としてご |
| 2007年12月03日 カラフルなオーガニックコットンのベビー服を販売しているyugaは、１２月７日にオーガニックコットン歯切れを利用したの手作りワークショップを開催します。場所は板橋のコミュニティカフェ「はぴくす」（http://www.happycs.jp/）にて１０時から。 第一弾の今回はスタイ（よだれかけ）を皆さんと作ろうと思います。 赤ちゃんがいる方、これから産まれる方、どなたでも大歓迎です。皆様のご参加を心よりお待ちしています。 参加費：１５００円 （ランチセット、利用料込み） お子様づれもOKです。ただしお子様入場料が２５０円かかります。 会場の都合上、先着１０名様とさせていただきますので、「はぴくす」へ電話かEメールにてお早めにお申し込みください。 電話 03-6411-0011 Eメール: info@happycs.jp 主催 株式会社 優雅 www.yugacolor.com 取材、見学ご希望の方は安東裕美までご連絡下さい。 |
| 2007年12月03日 報道関係者各位 ======================================================================== パワーテクノロジー株式会社（所在地：東京都千代田区 代表：中島正三）は、 『スグソコ』は、主に繁華街にて、「今すぐトイレに行きたい」「今すぐ 検索対象となる設備・お店と地域は以下の通りです。 ■ 対象の設備・お店 ■ 対象のエリア 総計で4,000スポットを検索対象とし、スポットごとに、現地までのルート、 今後も本サービスを中心に、消費者のリアルなニーズに応えていけるよう ※「業界初」は当社調べ（2007年11月時点）
■お問い合わせ |
| 2007年12月03日 中国語通訳・翻訳の株式会社E&Sインターナショナル（平成１７年９月設立 東京都品川区西大井1-1-2-206/代表取締役社長山本栄吉）は英語教師、自習者向けにグリーンウッド・カナダ社製英会話教材のeラーニングサービスを12月1日より開始します。 《英語教師、自習者向けのeラーニング英会話教材のサービスを開始》 【主な特長】
《販売政策と目標》
（注２） ALTE = Association of Language Testers/ヨーロッパ語学検定協会 |
| 2007年12月03日 ティーエムシー株式会社はレアメタルのリサイクル・回収から精製、生産と3事業を完全に自社内でおこなっています。 あらゆる分野から発生する特殊金属スクラップを独自のノウハウで再資源化へと推し進めていくことがTMCの企業力です。
これからも特殊金属のリサイクルという命題を通じ、社会に貢献できる企業体として絶えまぬ改革と研究開発を通じて、”地球延命”の経営理念を実践してまいります。 この度、日本語版ホームページをリニューアルいたしました。 |
| 2007年12月03日 ティーエムシー株式会社はレアメタルのリサイクル・回収から精製、生産と3事業を完全に自社内でおこなっています。 あらゆる分野から発生する特殊金属スクラップを独自のノウハウで再資源化へと推し進めていくことがTMCの企業力です。
これからも特殊金属のリサイクルという命題を通じ、社会に貢献できる企業体として絶えまぬ改革と研究開発を通じて、”地球延命”の経営理念を実践してまいります。 この度、日本語版ホームページをリニューアルいたしました。 |
| 2007年12月03日 ACQULIA（アクリア）2.0のリリースについて 株式会社サンストリーム（代表取締役社長：辻口 智 http://www.sanstream.co.jp 以下、サンストリーム）は、12月3日、H.264(※1)コーデックベースの高画質動画ストリーミングソリューション「ACQULIA（アクリア）」の、初のメジャーバージョンアップとなる「ACQULIA 2.0」をリリースいたしました。
【製品および価格体系の改定】 併せて、モジュール毎の価格と同時接続1ユーザあたりの単価を設定し、通常のライセンスだけでなく、使用期間や用途を限定した安価なライセンスを設定するなど、価格体系の全面改定も行いました。例えばエントリー用としてACQULIA VODシステムを1年間の期限付きライセンスで構成すれば、100万円以下の初期投資にて導入が可能となります。 【用語説明】 【ACQULIAの基本機能】 今後、サンストリームは、多様な動画ストリーミングの活用シーンを想定し、基本となるストリーミングサーバ他、ACQULIAの各モジュールのさらなる機能向上を継続して行っていくとともに、着実なマーケティングをもとに、エンドユーザまたは配信事業者の利便性をさらに高めるため、必要な機能の開発を積極的に行ってまいります。 【パッケージ価格例】 【お問合せ先】 【関連リンク】 |
| 2007年12月03日 ■ホワイトホンは、インターホンと携帯電話を融合させた、受話器を取るだ けで会話のできる直通電話です。 ■携帯電話を接続して使用しますが、受話器を取るだけで指定先の電話と会 話のできる、世界初の画期的な製品です。 ■国内で同様製品のの販売は当社のみ、アイデア次第で用途は無限です、他 社との競合は一切無い製品です。 ■製品はＨＰで、インターフォン・モバイル２と紹介されています、詳細は ＨＰをご覧下さい。 ■用途事例 ■「ホワイトホン」販売代理店のお問合せは |
| 2007年12月03日 インターネットを活用したマーケティングソリューションを提案する株式会社エイジア（本社：東京都品川区、社長：江藤 晃、以下当社）は、自社開発したe-CRMシステム「WEB CAS」シリーズ（http://webcas.azia.jp/）のメール共有管理システム「WEB CAS mailcenter」（http://webcas.azia.jp/mailcenter/index.html）を、携帯電話向けコンテンツ配信事業等を行う株式会社アイフリーク（本社：福岡県福岡市、社長：永田 万里子、以下アイフリーク）に提供いたしました。 アイフリークは、携帯電話向けHTMLメール（※）素材のコンテンツ配信を中心に、エンターテインメント性を重視したモバイルコンテンツプロバイダとして、コミュニケーションビジネスの創造に取り組んでいます。主に「デコメ★コレクション」などの携帯電話向けHTMLメール素材配信ポータルサイトをはじめ、電子コミック、待受画像、ゲームなどのデジタルコンテンツを提供するモバイルサイトを企画・制作・運営しております。 このたび同社では、各サイトの会員からの問い合わせに、より迅速かつ適切に対応して顧客満足度を向上させるため、社内のサポート体制の再構築を実施し、合わせて問い合わせメールを一元管理するシステムを採用することといたしました。 ＜メール共有管理システム「WEB CAS mailcenter」について＞
（※） 携帯電話向けHTMLメール とは ■株式会社アイフリークの概要 ■株式会社エイジアの概要
|
| 2007年12月03日 □■□■□■□■□■□■□■□■□■□■□■□■□■□■□■□■□■□ ■掲載企業大幅増加、掲載企業検索システムバージョンアップにより、 ■マーケティング支援.jpを基点として生まれた企業提携による新商品 ■デジタルブック技術「リアルリード」により、アイ・エム・プレス出版物 マーケティング支援.jpプロジェクト（主催：株式会社アイ・エム・プレス サイト表現も、Flashによる動画表現、デジタルブック表現を装備する 近年、関心の高まっているCRM、コールセンター、ダイレクトマーケティ 「マーケティング支援.jp」では、立ち上げ当初からの“売るための機能” 変化の激しいマーケティング環境にあって、ビジネスを成功に導くため 詳細は以下のとおりです。 1．今回、新たに掲載する主な企業 （1）スプリームシステムコンサルティング株式会社 （2）RealRead Inc CRM対応デジタルブック技術「リアルリード」 （3）通販惑星株式会社、株式会社WEMA、クレス株式会社、 2．検索システムのバージョンアップ 9月25日のプレオープン以来、お客様の声を収集し、様々なニーズ 3．マーケティング支援.jpコラボレーション商品第一弾「デカEC」 「デカEC」は、マーケティング支援.jpに参加するクレス(株)のモバイル 「デカEC」は、携帯電話の小さな画面でも簡単なキー操作で自由自在 モバイル画像拡大サービス「デカフラ」に関しましては、無料お試しキャ マーケティング支援.jpでは「デカEC」を第一弾と考え、マーケティング 4、デジタルブック技術「リアルリード」を採用し、アイ・エム・プレス出版 閲覧者のニーズにお応えし、パートナー選びの指針となるマーケティング １、全文書SEO対策、 などです。 今後、「マーケティング支援.jp」では総合的なマーケティング支援サイト □ ■マーケティング支援.jpについて■□ “インターネット時代の顧客づくりを活性化する”マーケティング情報誌、 マーケターが抱える課題を解決すると同時に、ITやアウトソーシングなど ※ Internet Explorer 6.0以前のブラウザをご利用の方は ＜株式会社アイ・エム・プレスの概要＞
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ |
| 2007年12月03日 中高年のコミュニティサイト『A-ha』会員数２０００人を突破 株式会社アイ・プランニング(本社:群馬県伊勢崎市、代表取締役:森岡 また、会員数増加に伴い、下記のように着実にアクセス増を得ることができました。 中高年層には、インターネットのコミュニケーションが活発でないイメージがありますが、 ーーーーーーーーーーーーーーーーーーーーーーーーーーーーーーーー |
| 2007年12月03日 報道関係者各位 ㈱アイコールは、NTT DoCoMoの公式コンテンツ向けに高品質で実施しておりました「きせかえツール」制作を一般（勝手）サイト向けに拡大いたします。モバイルサイトのコンテンツ拡充や企業PR用のツールとしてご活用頂けます。 その他製品のご案内
|
| 2007年12月03日 ================================================
キャンパスの中で友人同士が語り合う姿や、 収録の写真素材は、すべてロイヤリティフリーなので、
▼sozaijiten.com（データクラフト 商品情報URL） ■データクラフトについて デザイナー向けのECサイト ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 【本商品に関する問い合わせ先】 |
| 2007年12月03日 焼肉の大同門が新たなコンセプトで神戸三宮に2007年12月10日にNEW STYLEの焼肉店「神戸 星流苑」をオープンさせていただきます。 [神戸星流苑の名前の由来] 「豊かな海と山並みに囲まれた町「神戸｣ [商品へのこだわり] 「新鮮な地元の食材をその地で美味しく食べる」「地産地消」の考えから、 [店内イメージ] エントランスは、ウォーターカーテンでお出迎えいたします。 『レセプション 開催日時』 「日時」12月6日（木）18時00分～20時30分 「場所」兵庫県神戸市中央区北長狭通１－９－３ TEL 078-325-1400 FAX 078-325-1401
担当 綾城高志（あやしろたかし） t_ayashiro@daidomon.com |
| 2007年12月03日 ～ .NET Framework が GIS を変える ～ 業界初の .NETテクノロジーを使ったプラグイン型 GIS 開発環境 MapQuestSimpleApplicationFramework【構築 Pro】のご紹介セミナーを無料開催。定員残りわずかですのでお申込はお早めに。
●セミナーの詳細はこちらをご覧下さい。
■第1部 GISエンジン ： MapQuestDotNET ■第2部 プラグイン型GIS開発環境 ： 構築Pro ■第3部 WebGISエンジン ： MapQuestWebサーバーコントロール ■質疑応答 ------------------------------------------------------------------- ■日 時：2007年12月10日（月）13:30～16:30（受付開始：13:00より） |
| 2007年12月03日 株式会社オンテックス（大阪府大阪市）の代表取締役会長兼CEO小笹公也は、株式会社リンクアンドモチベーション（東京都中央区）の代表取締役社長 小笹芳央氏との共著により、2007年11月22日に、『自分のカラを破る力が湧く言葉』を株式会社経済界より発刊致しました。 【本書の特徴】 （２）対照的な二人の人生論対談！ 【概要】 【著者プロフィール】
■株式会社オンテックス http://www.ontex.co.jp/ |
| 2007年12月03日 報道関係者各位 甲乙株式会社（東京都世田谷区、代表取締役：小泉健司）は、本日2007年12月1日よりスポットランキングサイト『甲乙スポットランキング』（http://www.kouotu.com/）を運用開始いたしました。『甲乙スポットランキング』は、店などのスポットをみんなでランキングし、ランキングを統計した結果をみんなの意見としてスポット検索できる、地域に特化したソーシャルネットワーキングサービスです。 《サイトの特徴》 《サイトのねらい》 《サイトの概要》 ―――――――――――――――――――――――――――――――――― |